arrow
A

Antoni Ribas

University of California Los Angeles
H指数:158
被引数:16.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

作者更正:PAK4 抑制可增强 PD-1 阻断免疫疗法

2026-10-090
PRE
Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

全蛋白质筛选和多模态分析抗原特异性CD4+ T细胞在单细胞分辨率

2026-05-120
OAAI
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

顺序转录波和nf-κb驱动的染色质重塑直接药物诱导的癌症去分化

2026-04-150
OAAI
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

使用Trikine免疫治疗剂重塑细胞表面的STAT信号通路

Science
IF45.8
2026-02-190
PRE
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

可手术切除的增生性黑色素瘤的新辅助PD-1阻滞: SWOG S1512 2期试验的队列A

2026-01-290
OAAI
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

不可切除的增生性黑色素瘤的Anti-PD-1治疗: SWOG S1512 2期试验

2025-08-140
PRE
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study

肿瘤内注射vidutolimod作为单药治疗或与pembrolizumab联用,用于程序性细胞死亡1阻滞剂耐药性黑色素瘤患者的最终分析:一项1b期研究的结果

Cancer
IF5.1
2025-08-030
OAAI
CONQUERING SPP1+MYELOID-DRIVEN RESISTANCE OF GLIOBLASTOMA TO IL13RA2-TARGETED CAR T CELL THERAPY
2024-11-110
PRE
KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma

KEYMAKER 02B:一项关于帕博利珠单抗(pembro)单药或联合试验性药物作为晚期黑色素瘤一线治疗的随机试验

2024-09-012
PRE
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
2024-07-010
PRE
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
2024-03-220
PRE